Ricevi le ultime notizie sulle azioni Organon con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di OGN

Ultime notizie per

ORGANON & CO

Organon

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Gli analisti più esperti indicano 3 società con rendimenti consistenti. Un&#39;analisi approfondita per un portafoglio più stabile e redditizio.

Dividendi da urlo nel settore sanitario! 3 titoli segnalati dagli esperti

Organon & Co

Origin Protocol - United States dollar

OROGEN ROYALTIES INC by Orogen Royalties Inc

Orogen Royalties Inc

Orogen Royalties Inc.

ORGANA TECHS GRP INC by Organa Technologies Group, Inc.

Legal

Press Releases

ORGANON FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit

Organon & Co. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN

Contact Levi & Korsinsky by July 22, 2025 Deadline to Join Class Action Against Organon & Co.(OGN)

Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses. July 22, 2025 Deadline to file Lead Plaintiff Motion

Organon Reports Results for the Second Quarter Ended June 30, 2025

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Kuehn Law Encourages Investors of Organon & Co. to Contact Law Firm

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

ATAI Life Sciences

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals

Axsome Therapeutics

BGM Group

Bausch Health Companies Inc. Common Stock

Bausch Health Companies

Belite Bio, Inc - American Depositary Shares

Belite Bio

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harrow

Indivior

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Liquidia

Ocular Therapeutix

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pharvaris

Perrigo

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Comments

Organon Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO